This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kandzari, D. E. Search for Related Content PubMed PubMed Citation Articles by Kandzari, D. E.

Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization

David E. Kandzari, MD^*,*, Peter B. Berger, MD^*, Adnan Kastrati, MD, Steven R. Steinhubl, MD, Julinda Mehilli, MD, Franz Dotzer, MD, Jurriën M. ten Berg, MD^||, Franz-Josef Neumann, MD^¶, Hildegard Bollwein, MD^#, Josef Dirschinger, MD^#, Albert Schömig, MD^,# ISAR-REACT Study Investigators

^* Duke Clinical Research Institute, Durham, North Carolina
Deutsches Herzzentrum, Munich, Germany
University of Kentucky School of Medicine, Lexington, Kentucky
Mediziniche Klinik I, Garmisch-Partenkirchen, Germany
^|| St. Antonius Ziekenhuis, Nieuwegein, the Netherlands
^¶ Herz-Zentrum, Bad Krozingen, Germany
^# 1. Medizinische Klinik rechts der Isar, Munich, Germany

View larger version (19K): [in a new window]   Figure 1 Kaplan-Meier event curves for 30-day occurrence of death, myocardial infarction (MI), or urgent revascularization relative to clopidogrel loading-dose interval.